Solving the defining challenge of our generation
Holmusk is building the largest Real-World Evidence platform, starting with behavioral health. Combining a leading behavioral health database with AI-powered analytics and digital solutions, we are advancing the frontier of evidence generation and fueling innovation.
We bring together a unique combination of end-to-end data, scalable digital tools, and AI-powered analytics all under one roof, rooted in behavioral health expertise.
Real-World Evidence
Enabling life sciences discovery with NeuroBlu, a seamless data and analytics platform
Learn More
AI-powered Analytics
Proprietary AI/ML approaches designed specifically for behavioral health
Learn More
Specialty EHR & digital solutions
Solutions that reach the whole ecosystem, from specialty EHR to patient-facing tools
Learn More
rows of data
patients
years of longitudinal data
clinical encounters
geographically-diverse health systems
NeuroBlu enables users to access the most robust proprietary behavioral health dataset of its kind with structured outcome measures and seamless AI-powered analytic tools.
learn more
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
•Substance use disorders: 255k+ patients
•Major depressive disorder: 251k+ patients
•Bipolar disorder: 134k+ patients
•Attention-deficit/hyperactivity disorder: 82k+ patients
•Post-traumatic stress disorder: 63k+ patients
•Schizoaffective disorder: 34k+ patients
•Schizophrenia: 33k+ patients
•Borderline personality disorder: 19k+ patients
•Autism spectrum disorder: 16k+ patients
•Clinical Global Impressions (CGI-I/CGI-S)
•Columbia-Suicide Severity Rating Scale (C-SSRS)
•Patient Health Questionnaire-9 (PHQ-9)
•The Daily Living Activities–20 (DLA-20)
•The Quick Inventory of Depressive Symptomatology (QIDS)
•Brief Bipolar Disorder Symptom Scale (BDSS)
•Positive Symptom Rating Scale (PSRS)
•Brief Negative Symptom Assessment (BNSA)
•Global Assessment of Functioning (GAF)
•Antidepressants
•Antipsychotics
•Anxiolytics
•Hypnotics and sedatives
•Mood stabilizers
•Psycholeptics
•Psychostimulants
Learn More
.png)
HolCare EHR+ is a cloud-based, state-of-the-art electronic health records platform for behavioral health with innovative features such as fully integrated measurement-based care.
mHaven is a well-being solution that empowers individuals with tailored support to take charge of their mental and emotional wellness.
mConnect is a patient-centric solution designed to personalize care and treatment outcomes of patients with Major Depressive Disorder.
